Kinnunen Tuure, Buhot Cecile, Närvänen Ale, Rytkönen-Nissinen Marja, Saarelainen Soili, Pouvelle-Moratille Sandra, Rautiainen Jaakko, Taivainen Antti, Maillère Bernard, Mäntyjärvi Rauno, Virtanen Tuomas
Department of Clinical Microbiology, University of Kuopio, Finland.
Eur J Immunol. 2003 Jun;33(6):1717-26. doi: 10.1002/eji.200322952.
We have proposed earlier that the poor capacity of the lipocalin allergen Bos d 2 to stimulate highly allergic subjects' peripheral blood mononuclear cells could be ascribed to endogenous lipocalins and could be related to the allergenic potential of the molecule. Here, we have characterized the proliferative and cytokine responses of human T cell clones against the immunodominant epitope of Bos d 2. We observed, for clone F1-9, that a substitution of aspartic acid for asparagine in the core region of the epitope increased the stimulatory capacity of the peptide about 100-fold in comparison with the natural peptide. For clone K3-2, from a different patient, the substitution of lysine for glutamine or isoleucine for leucine in the core region resulted in about 30-fold and 10-fold increases in the stimulatory capacity of the peptides, respectively. The clones also recognized self-protein-derived peptides but not the peptides derived from other lipocalins. We suggest that the poor recognition of the immunodominant epitope of Bos d 2 can be a factor accounting for Bos d 2-allergic subjects' weak cellular responses. Suboptimal recognition of self and allergen epitopes by T cells may be of significance for the allergenicity of proteins.
我们之前曾提出,脂质运载蛋白过敏原Bos d 2刺激高过敏受试者外周血单个核细胞的能力较差,这可能归因于内源性脂质运载蛋白,并且可能与该分子的致敏潜力有关。在此,我们对人T细胞克隆针对Bos d 2免疫显性表位的增殖和细胞因子反应进行了表征。对于克隆F1-9,我们观察到,表位核心区域中天冬酰胺被天冬氨酸取代后,与天然肽相比,该肽的刺激能力提高了约100倍。对于来自另一名患者的克隆K3-2,核心区域中谷氨酰胺被赖氨酸取代或亮氨酸被异亮氨酸取代,分别使肽的刺激能力提高了约30倍和10倍。这些克隆还识别自身蛋白衍生的肽,但不识别来自其他脂质运载蛋白的肽。我们认为,对Bos d 2免疫显性表位的识别不佳可能是导致Bos d 2过敏受试者细胞反应较弱的一个因素。T细胞对自身和过敏原表位的识别欠佳可能对蛋白质的致敏性具有重要意义。